Evaluating the Role of the Microbiome in Antidepressant Treatment in Adolescents.

Part of paid clinical trials in San Diego, California.

Sponsor
University of California, San Diego
Study ID
NCT06633497
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Depression in Adolescence

Eligibility Criteria

Sex
ALL
Age
13 Years - 17 Years
Healthy Volunteers
Accepted

Study Details

The goal of this observational study is to learn about the role of the human gut microbiome in antidepressant treatment response in adolescents with Major Depressive Disorder (MDD). Specifically, the study aims to collect microbiota samples of adolescents treated with fluoxetine, over the span of 8-weeks, to: * determine the influence of the microbiome on the efficacy of fluoxetine to treat adolescent depression. * test whether the gut microbiome from different timepoints can predict ultimate success of fluoxetine * investigate the interaction of gut microbiome composition and pharmacogenetic metabolizer status on steady-state plasma concentrations of fluoxetine. Depression symptom severity will be evaluated upon enrollment and 6-weeks into antidepressant treatment.

Key Dates

Start date
Nov 30, 2024
Status verified
Oct 2024
Primary completion
Sep 30, 2026
Completion
Oct 31, 2026

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Gut microbiome composition [ Time Frame: Stool samples will be collected at enrollment (baseline), then following enrollment: daily for the first 7 days and biweekly at weeks 2, 4, 6, and 8. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Rady Children's Hospital San DiegoSan DiegoCalifornia92123-

Find similar trials in San Diego, CA

Related Studies